Oncotype testing is a genomic test that analyzes genes inside a tumor to predict how likely a cancer is to come back and whether chemotherapy would actually help. It’s most commonly used in early-stage breast cancer, where the results are expressed as a Recurrence Score from 0 to 100. That single number can be the deciding factor in whether you need chemotherapy or can safely skip it and stick with hormone therapy alone.
The test doesn’t require a new procedure. It’s performed on tumor tissue already collected during a biopsy or surgery, which gets shipped to a specialized lab. Results typically come back within 7 to 10 days after the lab receives the sample.
How the Test Works
Oncotype DX (the most widely used version, made by Exact Sciences) measures the activity of 21 genes in breast tumor tissue. Sixteen of those genes are directly related to cancer behavior: some drive cell growth and division, some are linked to hormone receptor signaling, and others relate to how the tumor interacts with surrounding tissue. The remaining five are reference genes used to standardize the measurements.
The test uses a technique called reverse transcription polymerase chain reaction, which essentially reads how “turned on” each gene is. An algorithm then combines the activity levels of all 21 genes into a single Recurrence Score. A tumor with highly active growth genes scores higher. A tumor with strong hormone receptor activity and quiet growth genes scores lower. The result tells your oncologist something that standard pathology reports can’t: how your specific tumor is likely to behave over the next decade.
Who Is Eligible for the Test
Oncotype DX for breast cancer is designed for a specific group of patients: those with early-stage, hormone receptor-positive, HER2-negative tumors. These are cancers that grow in response to estrogen or progesterone but don’t overexpress the HER2 protein. Within that group, the test is used for patients with no lymph node involvement and, based on more recent research, for those with one to three positive lymph nodes.
If your tumor is hormone receptor-negative or HER2-positive, Oncotype testing generally won’t apply. Those cancers follow different biological pathways, and treatment decisions rely on other factors.
Understanding Your Recurrence Score
Based on results from the landmark TAILORx trial, Recurrence Scores for node-negative breast cancer break down into three categories:
- Low risk (0 to 10): The cancer has a low chance of returning. Hormone therapy alone is the standard recommendation.
- Intermediate risk (11 to 25): The cancer falls in a gray zone, but large clinical trials have clarified what this means for most patients.
- High risk (26 to 100): The cancer has a higher likelihood of recurrence, and chemotherapy added to hormone therapy provides a meaningful benefit.
The critical finding from TAILORx involved the intermediate group. Among more than 6,700 women with scores of 11 to 25, those who received hormone therapy alone did just as well as those who also got chemotherapy. At five years, the rate of disease-free survival was 92.8% with hormone therapy alone and 93.1% with both treatments. At nine years, the numbers were 83.3% and 84.3%, respectively. The difference was not statistically significant.
There’s one important exception. Premenopausal women and those under 50 with scores at the higher end of the intermediate range (16 to 25) may see a small benefit from chemotherapy. For this subgroup, the decision becomes a more nuanced conversation with an oncologist.
Results for Women With Positive Lymph Nodes
For years, Oncotype testing was limited to node-negative patients. The RxPONDER trial expanded its usefulness to women with one to three positive lymph nodes and a Recurrence Score of 0 to 25. The results, though, depend heavily on whether you’ve gone through menopause.
Postmenopausal women in this group can safely skip chemotherapy. Five-year disease-free survival was virtually identical whether they received chemotherapy plus hormone therapy (91.3%) or hormone therapy alone (91.9%). The same held true for distant recurrence: 94.4% in both groups. Adding chemotherapy provided no measurable benefit.
Premenopausal women told a different story. Those who received chemotherapy on top of hormone therapy had a 40% reduction in the risk of disease recurrence compared to hormone therapy alone. Five-year disease-free survival was 93.9% with both treatments versus 89.0% with hormone therapy only. The benefit for preventing distant spread was similarly strong, with a 42% reduction in risk. For premenopausal women with positive lymph nodes, even a low Recurrence Score doesn’t rule out chemotherapy.
Oncotype Testing for DCIS
A separate version of the test exists for ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer. The DCIS Score helps determine whether radiation therapy is needed after breast-conserving surgery. It uses a different scoring scale than the invasive breast cancer version:
- Low risk: Score below 39
- Intermediate risk: Score between 39 and 54
- High risk: Score above 54
Medicare covers the DCIS test when the patient has confirmed DCIS with no invasive disease, is considering breast-conserving surgery, and the result will directly influence whether radiation therapy is added. It’s not covered for patients who have already decided on or received a mastectomy.
Beyond Breast Cancer
Oncotype DX isn’t limited to breast cancer. A prostate cancer version analyzes 17 genes (12 cancer-related and 5 reference genes) from a biopsy sample and produces a Genomic Prostate Score on a 0 to 100 scale. It’s designed for men with early-stage prostate cancer who are deciding between immediate treatment and active surveillance, essentially watchful waiting with regular monitoring.
A colon cancer version also exists, using a 12-gene panel to assess recurrence risk in patients with stage II or III disease. The goal is similar: identifying which patients truly need chemotherapy after surgery and which ones are unlikely to benefit from it.
What the Process Looks Like
You won’t need an additional biopsy or blood draw. Your surgical or pathology team coordinates shipping a preserved tissue sample from your existing biopsy or surgery to the testing laboratory. The lab extracts RNA from the tumor, runs the gene expression analysis, and sends the report back to your oncologist.
The turnaround is relatively quick for a genomic test. Most results arrive within 7 to 10 days after the lab receives the specimen, though the total wait can be slightly longer depending on how quickly your hospital ships the sample. Some institutions have streamlined the coordination between surgery, pathology, and the testing vendor to minimize delays.
The Recurrence Score arrives as a number on a report your oncologist will review with you. It’s one piece of a larger picture that includes your tumor size, grade, lymph node status, and overall health. But for the specific question of “will chemotherapy help me,” it’s often the most informative piece of data available.